Share:
Share this content in WeChat
X
• Review •
Application and advances of magnetic resonance-guided adaptive radiotherapy in uterine malignancies
SHI Jiawei  XU Chen  SUN Hongzan 

DOI:10.12015/issn.1674-8034.2026.11.026.


[Abstract] Radiotherapy for uterine malignancies is undergoing a profound transformation from conventional image-guided approaches to magnetic resonance-guided adaptive radiotherapy (MRgART). By leveraging the superior soft-tissue contrast of magnetic resonance imaging (MRI), MRgART enables precise visualization of tumor targets and organs at risk (OAR), and employs an online adaptive workflow to adjust treatment plans in real time according to the daily anatomical variations, thereby improving target dose coverage while significantly reducing OAR doses. Previous reviews have predominantly focused on a single dimension either MR-Linac-based external beam radiotherapy or image-guided adaptive brachytherapy (IGABT) with few integrating the two within a unified framework. In contrast, this review jointly examines online MR-guided adaptive radiotherapy (oMRgRT) based on MR-Linac and MRI-guided IGABT as two complementary branches of a full-course adaptive strategy for uterine malignancies. Regarding oMRgRT, beyond delineating the dosimetric benefits of target margin reduction and OAR dose sparing, this review highlights the strategy of simultaneous integrated boost to involved lymph nodes and the indication criteria for oMRgRT as an alternative boost when brachytherapy is not feasible. Regarding IGABT, this review goes beyond conventional summaries of target volume concepts and dose-volume histogram parameters by incorporating longitudinal evidence from the EMBRACE study series on shifting patterns of failure and patient-reported outcomes, thereby extending the evaluation dimension to patient-centered comprehensive endpoints. In addition, the level of evidence for both technical approaches in cervical and endometrial cancer is graded according to the Oxford Centre for Evidence-Based Medicine (OCEBM) criteria to facilitate appraisal of their clinical credibility. Furthermore, this review explores how emerging technologies including functional MRI, artificial intelligence-assisted segmentation and plan optimization, and radiomics may drive the evolution from anatomy-based to biology-based adaptation. MRgART holds the promise of further improving the therapeutic ratio in radiotherapy for uterine malignancies and enhancing patient outcomes and quality of life through the integration of MRI-guided adaptation across the full course of external beam radiotherapy and brachytherapy.
[Keywords] uterine neoplasms;radiotherapy;adaptive radiotherapy;magnetic resonance imaging;linear accelerator

SHI Jiawei1   XU Chen2   SUN Hongzan1, 2*  

1 College of Medical Imaging, Shanxi Medical University, Taiyuan 030000, China

2 Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China

Corresponding author: SUN H Z, E-mail: sunhongzan@126.com

Conflicts of interest   None.

Received  2026-07-23
Accepted  2026-10-21
DOI: 10.12015/issn.1674-8034.2026.11.026
DOI:10.12015/issn.1674-8034.2026.11.026.

[1]
LI Z, LIU P L, YIN A J, et al. Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer[J]. Int J Cancer, 2025, 157(2): 288-297. DOI: 10.1002/ijc.35369.
[2]
CORR B R, ERICKSON B K, BARBER E L, et al. Advances in the management of endometrial cancer[J/OL]. Bmj, 2025: e080978 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40044230/. DOI: 10.1136/bmj-2024-080978.
[3]
PENG S Y, ZHENG Y. Risk stratification and adjuvant treatment choice of endometrial cancer based on molecular typing: interpretation of ESGO-estro-ESP, ESMO and NCCN guidelines[J]. J Pract Obstet Gynecol, 2023, 39(10): 746-751.
[4]
HUANG C C, AYALA-PEACOCK D N, STEPHENS S J, et al. Recent advances in gynecologic radiation oncology[J/OL]. Cancer, 2025, 131(9): e35888 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40318035/. DOI: 10.1002/cncr.35888.
[5]
RONSINI C, SOLAZZO M C, BRACA E, et al. Locally advanced cervical cancer: neoadjuvant treatment versus standard radio-chemotherapy-an updated meta-analysis[J/OL]. Cancers, 2024, 16(14): 2542 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/39061182/. DOI: 10.3390/cancers16142542.
[6]
LEE J, LAPUZ C, KHOR R, et al. Narrative review of the utility of magnetic resonance imaging in radiotherapy for cervical cancer[J/OL]. Chin Clin Oncol, 2024, 13(2): 23 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38644546/. DOI: 10.21037/cco-23-91.
[7]
YEN A, CHOI B, INAM E, et al. Spare the bowel, don't spoil the target: optimal margin assessment for online cone beam adaptive radiation therapy (OnC-ART) of the cervix[J/OL]. Pract Radiat Oncol, 2023, 13(2): e176-e183 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/36356834/. DOI: 10.1016/j.prro.2022.10.009.
[8]
STURDZA A E, KNOTH J. Image-guided brachytherapy in cervical cancer including fractionation[J]. Int J Gynecol Cancer, 2022, 32(3): 273-280. DOI: 10.1136/ijgc-2021-003056.
[9]
BOEMI S, PAVAN M, SIENA R, et al. Locally advanced cervical cancer: multiparametric MRI in gynecologic oncology and precision medicine[J/OL]. Diagnostics (Basel), 2025, 15(22): 2858 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41300883/. DOI: 10.3390/diagnostics15222858.
[10]
LI M, RAN L, CHANG J Y. Application of imaging technology in image-guided brachytherapy for cervical cancer[J]. Pract Oncol J, 2021, 35(3): 263-267. DOI: 10.11904/j.issn.1002-3070.2021.03.013.
[11]
WESTERHOFF J M, DAAMEN L A, CHRISTODOULEAS J P, et al. Safety and tolerability of online adaptive high-field magnetic resonance-guided radiotherapy[J/OL]. JAMA Netw Open, 2024, 7(5): e2410819 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38691356/. DOI: 10.1001/jamanetworkopen.2024.10819.
[12]
PÖTTER R, TANDERUP K, SCHMID M P, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study[J]. Lancet Oncol, 2021, 22(4): 538-547. DOI: 10.1016/S1470-2045(20)30753-1.
[13]
PÖTTER R, TANDERUP K, KIRISITS C, et al. The embrace ii study: The outcome and prospect of two decades of evolution within the gec-estro gyn working group and the embrace studies[J]. Clin Transl Radiat Oncol, 2018, 9: 48-60. DOI: 10.1016/j.ctro.2018.01.001.
[14]
ORLANDO N, CROSBY J, GLIDE-HURST C, et al. Magnetic field quality conversion factors experimentally measured in clinical MR-linac beams for seven MR-compatible ionization chamber models[J/OL]. J Appl Clin Med Phys, 2025, 26(3): e14613 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/39673528/. DOI: 10.1002/acm2.14613.
[15]
BRYANT J M, WEYGAND J, KEIT E, et al. Stereotactic magnetic resonance-guided adaptive and non-adaptive radiotherapy on combination MR-linear accelerators: current practice and future directions[J/OL]. Cancers, 2023, 15(7): 2081 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/37046741/. DOI: 10.3390/cancers15072081.
[16]
GHAFARIAN M, CAO M S, KIRBY K M, et al. Magnetic resonance imaging sequences and technologies in adaptive radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2025, 122(4): 805-817. DOI: 10.1016/j.ijrobp.2025.04.017.
[17]
YAN L L, WANG N Y, ZHANG K, et al. Development and validation of a magnetic resonance imaging-guided adaptive radiotherapy workflow for long, continuous planning target volumes[J/OL]. Technol Cancer Res Treat, 2026, 25: 15330338251408324 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41553767/. DOI: 10.1177/15330338251408324.
[18]
DONA LEMUS O M, CAO M S, CAI B, et al. Adaptive radiotherapy: next-generation radiotherapy[J/OL]. Cancers, 2024, 16(6): 1206 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38539540/. DOI: 10.3390/cancers16061206.
[19]
ALSHAMRANI A, CHUTER R, AZNAR M, et al. Quantifying the dosimetric impact of online daily adaptation for MR-guided RT in cervical cancer[J]. Acta Oncol, 2025, 64: 693-702. DOI: 10.2340/1651-226X.2025.42898.
[20]
SHEPHERD M, WILLIAMS B, DINKLA A, et al. Online adaptive radiotherapy: International strategies for AI-enabled workflow efficiency and radiation therapist-led delivery for sustainable practice[J/OL]. Tech Innov Patient Support Radiat Oncol, 2026, 39: 100413 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/42292032/. DOI: 10.1016/j.tipsro.2026.100413.
[21]
LANGNER D, NACHBAR M, RUSSO M L, et al. Comparative analysis of open-source against commercial AI-based segmentation models for online adaptive MR-guided radiotherapy[J/OL]. Z Med Phys, 2025: S0939-S3889(25)00077-7 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40345918/. DOI: 10.1016/j.zemedi.2025.04.008.
[22]
LI Z J, ZHANG W, LI B S, et al. Patient-specific daily updated deep learning auto-segmentation for MRI-guided adaptive radiotherapy[J]. Radiother Oncol, 2022, 177: 222-230. DOI: 10.1016/j.radonc.2022.11.004.
[23]
WANG G Y, WANG Z Q, GUO Y P, et al. Evaluation of PTV margins with daily iterative online adaptive radiotherapy for postoperative treatment of endometrial and cervical cancer: a prospective single-arm phase 2 study[J/OL]. Radiat Oncol, 2024, 19(1): 2 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38178254/. DOI: 10.1186/s13014-023-02394-2.
[24]
BRANCO D, MAYADEV J, MOORE K, et al. Dosimetric and feasibility evaluation of a CBCT-based daily adaptive radiotherapy protocol for locally advanced cervical cancer[J/OL]. J Appl Clin Med Phys, 2023, 24(1): e13783 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/36208134/. DOI: 10.1002/acm2.13783.
[25]
HARIPOTEPORNKUL N H, NATH S K, SCANDERBEG D, et al. Evaluation of intra- and inter-fraction movement of the cervix during intensity modulated radiation therapy[J]. Radiother Oncol, 2011, 98(3): 347-351. DOI: 10.1016/j.radonc.2010.11.015.
[26]
PORTELANCE L, ASHER D, LLORENTE R, et al. Potential to reduce margins and Shrink targets in patients with intact cervical cancer treated on An MRI guided radiation therapy (MRgRT) system[J/OL]. Phys Med, 2025, 129: 104869 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/39671905/. DOI: 10.1016/j.ejmp.2024.104869.
[27]
VISSER J, DE BOER P, CRAMA K F, et al. Dosimetric comparison of library of plans and online MRI-guided radiotherapy of cervical cancer in the presence of intrafraction anatomical changes[J/OL]. Radiat Oncol, 2019, 14(1): 126 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/31300000/. DOI: 10.1186/s13014-019-1322-0.
[28]
PORTELANCE L, CORRADINI S, ERICKSON B, et al. Online magnetic resonance-guided radiotherapy (oMRgRT) for gynecological cancers[J/OL]. Front Oncol, 2021, 11: 628131 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/34513656/. DOI: 10.3389/fonc.2021.628131.
[29]
MURR M, BERNCHOU U, BUBULA-REHM E, et al. A multi-institutional comparison of retrospective deformable dose accumulation for online adaptive magnetic resonance-guided radiotherapy[J/OL]. Phys Imaging Radiat Oncol, 2024, 30: 100588 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38883145/. DOI: 10.1016/j.phro.2024.100588.
[30]
WHITE I, MCQUAID D, GOODWIN E, et al. Image guided adaptive external beam radiotherapy (EBRT) planning for cervical cancer - a comparison of offline, online and MRI-guided techniques to reduce organ at risk (OAR) dose using a dose accumulation model[J]. Int J Radiat Oncol, 2019, 105(1): S250-S251. DOI: 10.1016/j.ijrobp.2019.06.373.
[31]
OBANDO-RODRÍGUEZ J S, VIEIRA-SERNA S, PERALTA J, et al. Para-aortic lymph node staging and oncologic outcomes in locally advanced cervical cancer: A narrative review[J/OL]. Cancers, 2026, 18(13): 2058 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/42449603/. DOI: 10.3390/cancers18132058.
[32]
GUIGO M, DAUDA M S, LEQUESNE J, et al. Simultaneous integrated boost on pathologic lymph nodes safely improves clinical outcomes compared to sequential boost in locally advanced cervical cancer: a multicenter retrospective study[J/OL]. Front Oncol, 2024, 14: 1353813 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38887236/. DOI: 10.3389/fonc.2024.1353813.
[33]
ROMANO A, VOTTA C, NARDINI M, et al. Uterus motion analysis for radiotherapy planning optimization. The innovative contribution of on-board hybrid MR imaging[J/OL]. Clin Transl Radiat Oncol, 2024, 47: 100808 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/39005509/. DOI: 10.1016/j.ctro.2024.100808.
[34]
WARK A, HÜFNER L, MEIXNER E, et al. Clinical impact of MRI-guided intracavitary–interstitial brachytherapy in the curative management of advanced-stage cervical cancer[J/OL]. Curr Oncol, 2025, 32(3): 136 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40136340/. DOI: 10.3390/curroncol32030136.
[35]
FAYE M D, ALFIERI J. Advances in radiation oncology for the treatment of cervical cancer[J]. Curr Oncol, 2022, 29(2): 928-944. DOI: 10.3390/curroncol29020079.
[36]
VAN NOORTWIJK R, KROON P S, VAN VLIET-VAN DEN ENDE K M, et al. Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer[J/OL]. Clin Transl Radiat Oncol, 2026, 57: 101098 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41537166/. DOI: 10.1016/j.ctro.2025.101098.
[37]
JONES S, THOMPSON K, PORTER B, et al. Automation and artificial intelligence in radiation therapy treatment planning[J]. J Med Radiat Sci, 2024, 71(2): 290-298. DOI: 10.1002/jmrs.729.
[38]
LINDEGAARD J C, PETRIC P, TAN L T, et al. Are we making progress in curing advanced cervical cancer: again [J]. Int J Gynecol Cancer, 2024, 34(12): 1940-1945. DOI: 10.1136/ijgc-2024-005572.
[39]
WANG L, ALEXANDER S, MASON S, et al. Carpe diem: making the most of plan-of-the-day for cervical cancer radiation therapy[J]. Pract Radiat Oncol, 2023, 13(2): 132-147. DOI: 10.1016/j.prro.2022.11.005.
[40]
National Cancer Center, National Quality Control Center for Cancer, Expert Committee of Radiotherapy Quality Control, et al. Guidelines for target delineation, planning design and quality control of 3D brachytherapy for cervical cancer(2025 edition)[J]. Chin J Radiat Oncol, 2026, 35(9): 850-862. DOI: 10.3760/cma.j.cn113030-20260303-00095.
[41]
HAIE-MEDER C, PÖTTER R, VAN LIMBERGEN E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3): 235-245. DOI: 10.1016/j.radonc.2004.12.015.
[42]
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix[R/OL]. ICRU Report 89, Bethesda: ICRU, 2013. https://academic.oup.com/jicru/article-abstract/13/1-2/NP/2379433redirectedFrom=fulltext&login=false.
[43]
PÖTTER R, HAIE-MEDER C, VAN LIMBERGEN E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology[J]. Radiother Oncol, 2006, 78(1): 67-77. DOI: 10.1016/j.radonc.2005.11.014.
[44]
MAHANTSHETTY U, POETTER R, BERIWAL S, et al. IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer[J]. Radiother Oncol, 2021, 160: 273-284. DOI: 10.1016/j.radonc.2021.05.010.
[45]
VAN VLIET-VAN DEN ENDE K M, HOOGENDOORN-MULDER P G, SCHOKKER R I, et al. Adaptive brachytherapy for cervical cancer in combined 1.5 T MR/HDR suite: Impact of repeated imaging[J/OL]. Tech Innov Patient Support Radiat Oncol, 2024, 31: 100262 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/39224832/. DOI: 10.1016/j.tipsro.2024.100262.
[46]
TANDERUP K, FOKDAL L U, STURDZA A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer[J]. Radiother Oncol, 2016, 120(3): 441-446. DOI: 10.1016/j.radonc.2016.05.014.
[47]
SCHMID M P, LINDEGAARD J C, MAHANTSHETTY U, et al. Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study[J]. J Clin Oncol, 2023, 41(10): 1933-1942. DOI: 10.1200/JCO.22.01096.
[48]
VÉGVÁRY Z, KÓSZÓ R, EGYÜD Z, et al. MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience[J/OL]. Pathol Oncol Res, 2025, 31: 1612077 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40376012/. DOI: 10.3389/pore.2025.1612077.
[49]
ZHU Y G, ZHAO H F, CHENG G H, et al. A comparative study of CT-and MRI-based three-dimensional conformal brachytherapy for locally advanced cervical cancer[J]. Chin J Radiat Oncol, 2015, 24(4): 408-413. DOI: 10.3760/j.issn.1004-4221.2015.04.019.
[50]
NAJJARI-JAMAL D, JUAREZ M, CORDOBA S, et al. The crucial role of advanced image-guided brachytherapy for locally advanced cervical cancer in the era of systemic treatment intensification[J/OL]. Cancers, 2025, 17(11): 1809 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40507290/. DOI: 10.3390/cancers17111809.
[51]
IBIS K, ILGIN C, SUNCAK L, et al. Prognostic significance of nomogram and T-score in locally advanced cervical cancer patients treated with curative chemoradiotherapy and image-guided brachytherapy: A single-center retrospective study[J/OL]. Diagnostics (Basel), 2025, 15(17): 2142 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40941630/. DOI: 10.3390/diagnostics15172142.
[52]
MANIYAR A I, ALVA R C, KOUSHIK K, et al. Enhancing brachytherapy in cervical cancer: Initial dosimetric experience and assessment of Tulip hybrid applicator - the Add-On advantage[J]. J Contemp Brachytherapy, 2026, 18(1): 32-39. DOI: 10.5114/jcb.2026.161423.
[53]
YANG B, HU Y P, YU S H, et al. Comparison of differences in hematogenous metastasis among cervical cancer patients by CT-guided three-tube intracavitary brachytherapy and hybrid intracavitary and interstitial brachytherapy[J/OL]. Discov Oncol, 2025, 16(1): 1339 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/40665137/. DOI: 10.1007/s12672-025-03202-x.
[54]
FLOWER E, BUSUTTIL G, COSGRIFF E, et al. Evaluation of plan quality, safety, and toxicity of brachytherapy for locally advanced cervical cancer in an Australian setting following changes in prescription and applicator design[J]. J Med Imaging Radiat Oncol, 2025, 69(2): 295-303. DOI: 10.1111/1754-9485.13811.
[55]
KILAR C R, BAJWA H K, PIFER P M, et al. Selection of hybrid applicators for adaptive cervical cancer brachytherapy: A practical guide[J]. J Contemp Brachytherapy, 2025, 17(6): 390-399. DOI: 10.5114/jcb.2025.158016.
[56]
ROGOWSKI P, ROTTLER M, WALTER F, et al. Clinical outcome of combined intracavitary/interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer[J]. Gynecol Oncol, 2022, 166(3): 576-581. DOI: 10.1016/j.ygyno.2022.06.019.
[57]
FOKDAL L, STURDZA A, MAZERON R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study[J]. Radiother Oncol, 2016, 120(3): 434-440. DOI: 10.1016/j.radonc.2016.03.020.
[58]
STURDZA A, PÖTTER R, FOKDAL L U, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study[J]. Radiother Oncol, 2016, 120(3): 428-433. DOI: 10.1016/j.radonc.2016.03.011.
[59]
TANDERUP K, PÖTTER R, LINDEGAARD J C, et al. Image guided intensity modulated external beam radiochemotherapy and MRI based adaptive brachytherapy in locally advanced cervical cancer: EMBRACE-II[R/OL]. EMBRACE II Study Protocol, 2019. [2026-07-14]. https://www.embracestudy.dk/UserUpload/PublicDocuments/EMBRACE%20II%20Protocol.pdf.
[60]
KNOTH J, NOUT R A, PÖTTER R, et al. Distant metastasis after chemoradiation and image guided adaptive brachytherapy in locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2025, 123(2): 503-512. DOI: 10.1016/j.ijrobp.2025.04.037.
[61]
VITTRUP A S, KIRCHHEINER K, PÖTTER R, et al. Overall severe morbidity after chemo-radiation therapy and magnetic resonance imaging-guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study[J]. Int J Radiat Oncol, 2023, 116(4): 807-824. DOI: 10.1016/j.ijrobp.2023.01.002.
[62]
CHARRA-BRUNAUD C, HARTER V, DELANNES M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study[J]. Radiother Oncol, 2012, 103(3): 305-313. DOI: 10.1016/j.radonc.2012.04.007.
[63]
PELIZZOLA M, TANDERUP K, CHOPRA S, et al. Co-occurrence of symptoms after radiochemotherapy in locally advanced cervix cancer patients: a cluster analysis[J]. Acta Oncol, 2023, 62(11): 1479-1487. DOI: 10.1080/0284186X.2023.2271252.
[64]
FOKDAL L, PÖTTER R, KIRCHHEINER K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer[J]. Radiother Oncol, 2018, 127(3): 423-430. DOI: 10.1016/j.radonc.2018.05.002.
[65]
NOORIAN F, HERREROS A, ABELLANA R, et al. Choosing between the best, the easiest and the most usual: Three different dose prescription methods for HDR vaginal-cuff brachytherapy planning in postoperative endometrial cancer[J]. Brachytherapy, 2025, 24(4): 515-523. DOI: 10.1016/j.brachy.2025.03.005.
[66]
KAMRAVA M, LEUNG E, BACHAND F, et al. GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina[J]. Int J Radiat Oncol Biol Phys, 2023, 115(3): 654-663. DOI: 10.1016/j.ijrobp.2022.09.072.
[67]
ROVIROSA A, NOORIAN F, CORDOBA S, et al. Where are we with fractionation schedules and prescriptions in high-dose-rate 3D planning vaginal cuff brachytherapy [J]. J Contemp Brachytherapy, 2024, 16(5): 352-361. DOI: 10.5114/jcb.2024.144183.
[68]
CHEN Y C, YEH C Y. Image-guided adaptive brachytherapy for uterine cancer: A comprehensive review[J/OL]. Cancers, 2026, 18(4): 693 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41749946/. DOI: 10.3390/cancers18040693.
[69]
PARSONS M W, HUANG Y J, BURT L, et al. Vaginal cuff brachytherapy for endometrial cancer: a review of major clinical trials with a focus on fractionation[J]. Int J Gynecol Cancer, 2022, 32(3): 311-315. DOI: 10.1136/ijgc-2021-002456.
[70]
AYACHI Z EL, GABRO A, CAMPRODON G, et al. Transformative clinical trials in gynaecologic radiation oncology in 2023-2024: Shaping modern treatment practices[J]. Cancer/Radiothérapie, 2024, 28(8): 719-726. DOI: 10.1016/j.canrad.2024.10.002.
[71]
CAUSA ANDRIEU P, AVESANI G, QUESADA S, et al. Endometrial cancer: a daily clinical practice guide for radiologists[J]. Magn Reson Med Sci, 2025, 24(3): 387-402. DOI: 10.2463/mrms.rev.2025-0004.
[72]
EUSTACE N, LIU J, LADBURY C, et al. Current status and future directions of image-guided adaptive brachytherapy for locally advanced cervical cancer[J/OL]. Cancers, 2024, 16(5): 1031 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/38473388/. DOI: 10.3390/cancers16051031.
[73]
CHEN Z S, FAN J J, WANG Z, et al. Application value of diffusion-weighted magnetic resonance imaging in early evaluation of radiotherapy and chemotherapy for cervical cancer[J]. Chin J Gerontol, 2021, 41(10): 2053-2055. DOI: 10.3969/j.issn.1005-9202.2021.10.012.
[74]
NEJAD-DAVARANI S, LUTSIK N, MITTAUER K, et al. Multi-center diffusion-weighted MRI validation for 0.35T MR-linac[J/OL]. Phys Med, 2026, 142: 105726 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41558339/. DOI: 10.1016/j.ejmp.2026.105726.
[75]
HU Y F, NGUYEN H, SMITH C, et al. Clinical assessment of a novel machine-learning automated contouring tool for radiotherapy planning[J/OL]. J Appl Clin Med Phys, 2023, 24(7): e13949 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/36871161/. DOI: 10.1002/acm2.13949.
[76]
PARCHUR A K, LIM S, NASIEF H G, et al. Auto-detection of necessity for MRI-guided online adaptive replanning using a machine learning classifier[J]. Med Phys, 2023, 50(1): 440-448. DOI: 10.1002/mp.16047.
[77]
PSOROULAS S, PAUNOIU A, CORRADINI S, et al. MR-linac: role of artificial intelligence and automation[J]. Strahlenther Und Onkol, 2025, 201(3): 298-305. DOI: 10.1007/s00066-024-02358-9.
[78]
PAIBOONBORIRAK C, ABU-RUSTUM N R, WILAILAK S. Artificial intelligence in the diagnosis and management of gynecologic cancer[J]. Int J Gynaecol Obstet, 2025, 171(Suppl 1): 199-209. DOI: 10.1002/ijgo.70094.
[79]
LI H L, LI X H, ZHANG J Q, et al. AI-assisted 3D-printed transvaginal template guidance for interstitial brachytherapy in patients with cervical cancer with parametrial invasion[J]. Brachytherapy, 2026, 25(1): 95-106. DOI: 10.1016/j.brachy.2025.10.011.
[80]
CUI D, ZHANG N, WANG J B, et al. Clinical efficacy analysis of MRI-guided adaptive brachytherapy for locally advanced cervical cancer[J]. Chin J Radiat Oncol, 2026, 35(9): 904-912. DOI: 10.3760/cma.j.cn113030-20260126-00045.
[81]
YAO Q L, WANG K Y, LIU B, et al. Integrated optimization of needle paths and dwell time for individualized template-guided interstitial brachytherapy[J/OL]. Med Phys, 2026, 53(4): e70411 [2026-07-14]. https://pubmed.ncbi.nlm.nih.gov/41912351/. DOI: 10.1002/mp.70411.

PREV Research progress on MRI assessment of extramural vascular invasion in rectal cancer
NEXT Advances in the clinical applications of multimodal quantitative MRI in sarcopenia
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn